Imescia is a pre-clinical biotech company developing a new platform technology called "polymer-drug conjugate" addressing unmet medical needs in oncology. The company is working on a pipeline of highly potent drugs that have very promising activities but toxicities that limit their development. The technology makes it possible to target tumors and improve the therapeutic index of these treatments.
Our latest study shows that polymer drug conjugate (PDC) technology achieves similar efficacy to antibody drug conjugate (ADC) technology while remaining simpler, less expensive and more flexible.
IMESCIA develops :
• a lead candidate, IMA-01, which has demonstrated safety and efficacy in several preclinical cancer models. It is
optimized and ready to enter non-clinical development.
• A pipeline of small molecules (immunotherapy, tyrosine kinase inhibitors) is under development. Apart from small molecules, the technology has been adapted to miRNAs.
IMESCIA is looking for Seed funding of 2 M€ to bring IMA-01 to the IND, consolidate the platform and find a first partner for one of the products in the pipeline.